bluebird bio Inc at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa Transcript
Thanks, Pascal. Now it's bluebird time with Jeff Walsh; Jeff's Chief Strategic Officer.
Good morning. I'm excited to be here. And it is bluebird time, I guess for the next 15 minutes at least.
So one of things that we've talked about as a company, and really, focused on throughout the history of the company is this concept of recoding. And this is the case for all of us in this field. We really have to change systems. We have to change the way we're developing these therapies, the way that we're delivering these therapies. And that's really where we are as a company right now, not only on the research side, development side, but now having to recode on the commercial side. So it's a really exciting time for us for sure.
I will be making forward-looking statements as well, so please refer to the SEC filings for more information on that in terms of the risks of the company.
When we talk about recoding for life is conveyed on this slide. It's the middle part of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |